BridgeBio price target raised to $98 from $93 at Piper Sandler

Piper Sandler raised the firm’s price target on BridgeBio (BBIO) to $98 from $93 and keeps an Overweight rating on the shares. The firm notes the company reported their Q3 earnings after the close, which included Attruby sales of $108.1M for the quarter, ahead of consensus of $102.4M and its estimate of $93M. While the investor bar remains high, Piper is encouraged by the steady increase in Attruby sales throughout its first year of the launch and continues to believe that it can be a market leader in the ATTRCM space.